Rafferty Asset Management, LLC Reata Pharmaceuticals Inc Transaction History

Rafferty Asset Management, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	BUY	$79.22 - $105.37 $271,249 - $360,786	3,424 New	3,424 $349,000
Q1 2022 May 13, 2022	SELL	$24.12 - $39.6 $276,174 - $453,420	-11,450 Closed	0 $0
Q4 2021 Feb 10, 2022	BUY	$25.61 - $110.96 $118,651 - $514,077	4,633 Added 67.96%	11,450 $302,000
Q3 2021 Nov 10, 2021	BUY	$100.0 - $143.02 $421,500 - $602,829	4,215 Added 161.99%	6,817 $686,000
Q2 2021 Aug 10, 2021	BUY	$78.27 - $151.29 $7,357 - $14,221	94 Added 3.75%	2,602 $368,000
Q1 2021 May 10, 2021	SELL	$94.25 - $132.81 $83,128 - $117,138	-882 Reduced 26.02%	2,508 $250,000
Q4 2020 Feb 10, 2021	SELL	$102.03 - $184.62 $35,914 - $64,986	-352 Reduced 9.41%	3,390 $419,000
Q3 2020 Nov 13, 2020	BUY	$93.53 - $163.34 $178,735 - $312,142	1,911 Added 104.37%	3,742 $365,000
Q2 2020 Aug 07, 2020	BUY	$126.3 - $176.56 $231,255 - $323,281	1,831 New	1,831 $286,000
Q1 2020 May 15, 2020	SELL	$124.16 - $247.74 $244,595 - $488,047	-1,970 Closed	0 $0
Q4 2019 Feb 10, 2020	SELL	$74.57 - $217.92 $94,853 - $277,194	-1,272 Reduced 39.24%	1,970 $403,000
Q3 2019 Nov 14, 2019	BUY	$71.26 - $95.75 $231,024 - $310,421	3,242 New	3,242 $260,000

62.7K

Ticker RETA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,583,200
Description
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney diseas...

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Rafferty Asset Management, LLC with notifications on news.